Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc > Saw this post on the ceo board posted today by BearTank
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(183)
•••
Post by milstogoon Jan 24, 2021 5:48pm
263 Views
Post# 32371857

Saw this post on the ceo board posted today by BearTank

Saw this post on the ceo board posted today by BearTank (hope he doesn't mind) but thought everyone here would be interested in reading it. REPOSTING:
@BearTank Happy Sunday fellas!! Just got off the phone with Thomas @HEM_CEO and @ticotime2020 And by the sounds of things that he was able to share, we are looking at some very exciting news that should be coming our way. To go in to some further detail regarding the last NR about the contract with the Dept of Foreign Affairs and Trade and Development Canada. This contract has given $HEM a pathway to one on one meetings with CEO's of BioTech companies in their respective countries. This is the only pathway for companies to get these one on one meetings to setup licensing agreements. Very exciting!! Also, $HEM will be attending the Biocom event in February in the US. This event is a huge opportunity for $HEM to get in front of some of the largest BioTech companies in the US. Here are a few links for information. #index #biotech Let the good times roll!!! Exciting times to be a $HEM shareholder!!! https://www.biocom.org/ https://biocomglobalpartnering.org/
@BearTank Happy Sunday fellas!! Just got off the phone with Thomas @HEM_CEO and @ticotime2020 And by the sounds of things that he was able to share, we are looking at some very exciting news that should be coming our way. To go in to some further detail regarding the last NR about the contract with the Dept of Foreign Affairs and Trade and Development Canada. This contract has given $HEM a pathway to one on one meetings with CEO's of BioTech companies in their respective countries. This is the only pathway for companies to get these one on one meetings to setup licensing agreements. Very exciting!! Also, $HEM will be attending the Biocom event in February in the US. This event is a huge opportunity for $HEM to get in front of some of the largest BioTech companies in the US. Here are a few links for information. #index #biotech Let the good times roll!!! Exciting times to be a $HEM shareholder!!! https://www.biocom.org/ https://biocomglobalpartnering.org/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities